1. Meneghini L, Reid T. Individualizing insulin therapy. Supplement to The Journal of Family Practice 2012; 61(5): S13-S26.
2. Peyrot M, Barnett AH, Meneghini LF, Schumm-Drager PM. Insulin Adherence Behaviors and Barriers in the Multi-national Global Attitudes of Patients and Physicians in Insulin Therapy (GAPP) Study. Diabetic Medicine 2012; 29: 682–689
3. Khunti K, Damci T, Meneghini L, Pan CY, Yale JF, on behalf of the SOLVE Study Group Study of Once Daily Levemir (SOLVETM): Insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes Obesity & Metabolism 2012 (accepted)
4. Home PD, Meneghini L, Wendisch U, Ratner RE, Johansen T, Christensen TE, Jendle J, Roberts AP, Birkeland KI. Improved health-related quality of life with insulin degludec compared with insulin glargine in people with type 1 diabetes. Diabetic Medicine 2012 (accepted)
5. Meneghini LF, Miranda-Palma B. Insulin Degludec: a novel ultra-long acting basal insulin for use in type 1 and type 2 diabetes. Expert Review of Endocrinology & Metabolism 2012; 7(1): 9-14
6. Chaudhuri A, Rosenstock J, DiGenio A, Meneghini L, Hollander P, McGill JB, Dandona P, Ilgenfritz J, Riddle M. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Diabetes Metabolism Research and Reviews 2011, Nov 12 [Epub ahead of print: doi 10.1002/dmrr.1305]
7. Meneghini LF. Insulin for intensifying diabetes treatment. J Fam Pract 2011; 60 (9 Suppl): S21-28
8. Meneghini LF, Orozco-Beltran D, Khunti K, Caputo S, Damçi T, Liebl A, Ross SA. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab 2011 Sep 7 [Epub ahead of print]
9. Han D, Leyva CA, Matheson D, Mineo D, Messinger S, Bloomberg BB, Hernandez A, Meneghini LF, Allende G, Skyler JS, Alejandro R, Pugliese A, Kenyon NS. Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes. Clinical Immunology 2011; 139: 290-301
10.Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. A comparison of two intensification regimens with rapid-acting insulin aspart in type 2 diabetes inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the STEP-Wise™ randomized study. Endocrine Practice 2011; 17: 727-736
11.Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, Lyby K, Jendle JH, Roberts AP, DeVries JH, Meneghini LF. Insulin Degludec in Type 1 Diabetes: a Randomized Controlled Trial of a New generation Ultra-long-acting Insulin Compared to Insulin Glargine. Diabetes Care 2011; 34: 661-665
12.Meneghini L, Sparrow-Bodenmiller J. Practical Aspects and Considerations When Switching Between Continuous Subcutaneous Insulin Infusion and Multiple Daily Injections. Diabetes Technology & Therapeutics 2010; 12 (Suppl 1): S109-S114
13.Meneghini LF, Traylor L, Schwartz, S. Improved Glycemic Control With Insulin Glargine Versus Pioglitazone as Add-On Therapy to Sulfonylurea or Metformin in Uncontrolled Type 2 Diabetes. Endocrine Practice 2010; 16(4): 588-599
14.Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group [Meneghini L]. Effectiveness of sensor-augmented insulin pump therapy in type 1 diabetes. NEJM 2010; 363: 311-320
15.Meneghini L. Introduction to Breaking Down Barriers to Insulin Management in Primary Care. Primary Diabetes Care 2010; 4 (supplement 1): S1-S2
16.Meneghini L, Liebl A, Abrahamson MJ. Insulin Detemir: A historical perspective on a modern basal insulin analog. Primary Diabetes Care 2010; 4 (supplement 1): S31-S42
17.Meneghini L, Artola S, Caputo S, Damci T, Dzida G, Kaiser M, Khunti K, Liebl A, Lighthelm R, Maran A, Orozco-Beltran D, Ross S, Yale JF. Practical guidance to insulin management. Primary Diabetes Care 2010; 4 (supplement 1): S43-S56.
18.Kennedy L, Solano M, Meneghini L, Lo M, Cohen M. Anti-Glycation and Anti-Albuminuric Effects of GLY-230 in Human Diabetes. American Journal of Nephrology 2010; 31: 110-116
19.Meneghini LF. Perioperative management of diabetes: Translating evidence into practice. Cleveland Clinic Journal of Medicine 2009; 76 (Suppl 4): S53-S59.
20.Meneghini LF. Early insulin treatment in type 2 diabetes: Pro Argument. Diabetes Care 2009; 32 (Suppl 2): S266-S269.
21.Selam JL, Meneghini LF. Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial. Adv Ther. 2009 Mar 2 [Epub ahead of print].
22.Meneghini LF, Dornhorts A, Sreenan S. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study. Curr Med Res Opin. 2009; March 13 [Epub ahead of print]
23.Meneghini LF, Hogan AR, Selvaggi G. Superior Mesenteric Artery Syndrome in Type 1 Diabetes Masquerading as Gastroparesis. Diabetes Care. 2008; 31(10): 1983-1984.
24.Meneghini LF. Insulin detemir: a long-acting insulin analog for the treatment of Type 1 and 2 diabetes. Therapy 2008; 5(4): 1-17
25.Meneghini L. Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient. Int J Clin Pract 2008; 62(8): 1255-1264
26.Meneghini L. Ethnic disparities in diabetes care: myth or reality? Curr Opin Endocrinol Diabetes Obes 2008; 15(2): 128-134
27.Dornhorst A, Luddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L on behalf of the PREDICTIVE Study Group. Insulin detemir improves glycemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE™ Study. International Journal of Clinical Practice 2008; 62: 659-665.
28.Selam JL, Koenen C, Weng W, Meneghini L. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Current Medical Research & Opinions 2008; 24: 11-20
29.Meneghini L, Koenen C, Wend W, Selam J. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes – results from the randomized, controlled PREDICTIVE 303 Study. Diabetes Obes Metab 2007; 9: 902-913
30.Meneghini LF, Florez H, Tamariz L. The Avandia Debacle: Methodology and Practical Importance of the Findings. Southern Medical Journal 2007; 100 (11) [Rapid Response section posted June 12, 2007]
31.Meneghini LF. Impact of Bariatric Surgery on Type 2 Diabetes. Cell Biochemistry and Biophysics 2007; 48 (2-3): 97-102
32.Laffel L, Hsu W, McGill J, Meneghini L, Volkening L on behalf of the Monitoring of Blood Glucose Study Group. Continued use of an integrated meter with electronic logbook maintains improvements in glycemic control beyond a randomized, controlled trial. Diabetes Technology & Therapeutics 2007; 9(3): 254-264
33.Meneghini L. Why and How to Use Insulin Therapy Earlier in the Management of Type 2 Diabetes. Southern Medical Journal 2007; 100(2): 164-74
34.Meneghini L, Horn Rosenberg K, Koenen C, Merilainen M, Luddeke H. Insulin detemir improves glycemic control with less hypoglycemia and no weight gain in patients with Type 2 diabetes who are insulin naïve or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007; 9: 418-427.
35.Meneghini L, Hirsch IB. Pharmacotherapies for diabetes management: an update for the practicing clinician. Semin Thorac Cardiovasc Surg 2006; 18(4): 379-389
36.Kahn SE, Haffner CB, Heise MA, et al for the ADOPT Study Group (Meneghini L). Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. NEJM 2006; 355: 2427-2443.
37.Knopp RH, D’Emden M, Smilde JG, Pocock Sj on behalf of the ASPEN Study Group (Meneghini LF). Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006; 29: 1478-1485.
38.Meneghini L, Florez H, Spadola J. Prevalence and Associations of Binge Eating Disorder in a Multi-Ethnic Population with Type 2 Diabetes. Diabetes Care 2006; 29 (12): 2760
39.Albisser AM, Alejandro RA, Meneghini LF, Ricordi C. How Good is your Glycemic Control? Diabetes Technol Ther 2005; 7: 863-875.
40.Geiger MC, Ferreira JV, Hafiz MM, Froud T, Baidal DA, Meneghini LF, Ricordi C, Alejandro R. Evaluation of metabolic control using a continuous subcutaneous glucose monitoring system in patients with type 1 diabetes mellitus who achieved insulin independence after islet cell transplantation. Cell Transplantation 2005; 14(2-3): 77-84.
41.Gaudiani LM, Lewin A, Meneghini L, Perevozskaya I, Plotkin D, Mitchel Y, Shah S. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab. 2005 Jan;7(1):88-97.
42.Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT, Oakes R, Lukas MA, Anderson KM, Bell DSH for the GEMINI Investigators (Meneghini LF). Metabolic Effects of Carvedilol vs Metoprolol in Patients with Type 2 Diabetes Mellitus and Hypertension: a Randomized Controlled Trial. JAMA 2004; 292: 2227-2236.
43.Ferchak CV and Meneghini LF. Obesity, Bariatric Surgery and Type 2 Diabetes - a Systematic Review. Diabetes Metabolism Research & Reviews 2004; 20: 438-445.
44.AJ Lewin, MS Kipnes, LF Meneghini, DJ Plotkin, IT Perevozskaya, S Shah, DL Maccubbin, JA Tobert. Simvastatin in Thiazolidinedione-Treated Type 2 Diabetic Patients: LDL-C Goal Attainment and Effects on the Lipid Profile. Clinical Therapeutics 2004; 26: 379-389
45.Meneghini LF. Physiologic Insulin Replacement: Insulin Pump Therapy (CSII) vs. Multiple Daily Insulin Injections (MDI). American Journal of Diabetes 2004, Vol. 1, No. 1.
46.Meneghini LF, Albisser AM, Goldberg RB, Mintz DH. An Electronic Case Manager for Diabetes Control. Diabetes Care 1998: 21: 591-596
47.Meneghini L, Oster J R, Camacho R C, Gkonos P J, Roos B A, Hypercalcemia in Association with Acute Renal Failure and Rhabdomyolysis: Case Report and Literature Review. Mineral and Electrolyte Metabolism 1993;19: 1-16.
